Log in to search using one of your social media accounts:

 

French Oncologists Upgrade Mesothelioma Standard of Care
Oncologists throughout France have joined the U.S.-based National Comprehensive Cancer Network (NCCN) in upgrading their recommended standard-of-care treatment regimen for unresectable pleural mesothelioma. Both groups have added bevacizumab (Avastin) to the traditional cisplatin and pemetrexed chemotherapy combination, expecting to see longer patient survival. “This is a major advancement for the care of mesothelioma patients,” Dr. Gerard Zalcman, head of thoracic oncology at Bichat-Claude Bernard Hospital, told Asbestos.com. “Clearly, this drug can change the natural history of this tumor.” Bevaci...
Source: Asbestos and Mesothelioma News - November 20, 2017 Category: Environmental Health Authors: Daniel King Tags: American Society of Clinical Oncology Avastin bevacizumab Bichat-Claude Bernard Hospital French Cooperative Thoracic Intergroup Gerard Zalcman National Comprehensive Cancer Network nintedanib Ofev pleural mesothelioma chemotherapy Source Type: news

Phase III IMpower150 study showed Roche ’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus chemotherapy significantly reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced lung cancer
Roche today announced that the Phase III IMpower150 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) plus chemotherapy (paclitaxel and carboplatin) provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death (PFS) compared to Avastin plus chemotherapy in the first-line treatment of people with advan ced non-squamous non-small cell lung cancer (NSCLC). Initial observations for the co-primary endpoint of overall survival (OS) are encouraging. These d...
Source: Roche Media News - November 20, 2017 Category: Pharmaceuticals Source Type: news

Phase III IMpower150 study showed Roche ’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus chemotherapy significantly reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced lung cancer
Roche today announced that the Phase III IMpower150 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) plus chemotherapy (paclitaxel and carboplatin) provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death (PFS) compared to Avastin plus chemotherapy in the first-line treatment of people with advan ced non-squamous non-small cell lung cancer (NSCLC). Initial observations for the co-primary endpoint of overall survival (OS) are encouraging. These d...
Source: Roche Investor Update - November 20, 2017 Category: Pharmaceuticals Source Type: news

EU Panel Likes Biosimilar Bevacizumab, Other Cancer Agents EU Panel Likes Biosimilar Bevacizumab, Other Cancer Agents
The Committee for Medicinal Products for Human Use has issued a new list of recommendations and rejections for oncology products.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 10, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer
First Avastin® (Bevacizumab) Biosimilar Candidate Recommended for European Approval THOUSAND OAKS, Calif., Nov. 10, 2017 -- (Healthcare Sales & Marketing Network) -- Amgen (NASDAQ: AMGN) and Allergan plc. (NYSE: AGN) today announced that the Commit... Biopharmaceuticals, Oncology, Regulatory Amgen, Allergan, biosimilar, Avastin, bevacizumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 10, 2017 Category: Pharmaceuticals Source Type: news

Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer
First Avastin® (Bevacizumab) Biosimilar Candidate Recommended for European Approval THOUSAND OAKS, Calif., Nov. 10, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the Marketing Authorization of ABP 215, a biosimilar to Avastin® (bevacizumab). ABP 215 has been recommended for approval for the treatment of certain types of cancer, including in combination with fluoropyrimidine-based chemotherapy for metastatic carcinoma of the colon or rec...
Source: Amgen News Release - November 10, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Review Shows Bevacizumab Has Gained Momentum for Mesothelioma...
The VEGF inhibitor is now part of the standard treatment for pleural mesothelioma in France and a recognized first-line option for American clinicians.(PRWeb November 06, 2017)Read the full story at http://www.prweb.com/releases/2017/11/prweb14884392.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 6, 2017 Category: Pharmaceuticals Source Type: news

Taxpayers pay twice for crucial drugs like Avastin | Letters
Big pharma companies are charging over the odds for medicines developed with public funding, writeHeidi Chow andTabitha HaIt is shocking, but not surprising, that big drugs companies are threatening to sue the NHS for using cheaper versions of drugs that could save people from going blind (Drug firms trying to stop cheap eye treatment on NHS, 1 November). Another part of this story is that the two medicines in question – Lucentis (known generically as ranibizumab) and Avastin (bevacizumab) are based on the groundbreaking discovery of monoclonal antibodies, whichwere developed with UK public funding.The NHS itself fun...
Source: Guardian Unlimited Science - November 5, 2017 Category: Science Authors: Letters Tags: NHS Drugs Medical research Science Health Society Pharmaceuticals industry Business Blindness and visual impairment Disability Source Type: news

Policy and regulation stand in the way of NHS use of unlicensed eye injection drug with potential to save millions of pounds
Eye injection drugs recommended by NICE cost the NHS up to £ 447 million annually, but could be replaced by an unlicensed drug, bevacizumab, costing as much as ten times less. Use of the two licensed drugs, ranibizumab and aflibercept, has increased three-fold over the last five years, with some parts of England treating five times as many patients as others. (Source: University of Bristol news)
Source: University of Bristol news - November 1, 2017 Category: Universities & Medical Training Tags: Health, Research; Faculty of Health Sciences, Faculty of Health Sciences, Bristol Medical School, Faculty of Health Sciences, Population Health Sciences; Press Release Source Type: news

Health chiefs facing legal fight over cheaper eye drug
Prescribing Avastin will save the NHS "millions of pounds", health bosses say. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - November 1, 2017 Category: Consumer Health News Source Type: news

Doctors face legal action over use of unlicensed eye drug
They want to prescribe Avastin for wet AMD rather than costlier alternatives Related items fromOnMedica UK patients losing out in access to cancer drugs Drug and Therapeutics Update UK ‘inadequate’ at regulating off-label drugs GMC steps into eye drug row Novartis accused of attempt to derail eye drug trials (Source: OnMedica Latest News)
Source: OnMedica Latest News - November 1, 2017 Category: UK Health Source Type: news

FDA accepts Roche ’s supplemental Biologics License Application for Avastin as a front-line treatment for women with advanced ovarian cancer
Roche announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) for Avastin ® (bevacizumab) in combination with chemotherapy (carboplatin and paclitaxel), followed by Avastin alone, for the front-line treatment of women with advanced ovarian cancer. (Source: Roche Investor Update)
Source: Roche Investor Update - October 26, 2017 Category: Pharmaceuticals Source Type: news

Mvasi (Bevacizumab-awwb Solution for Intravenous Infusion) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 27, 2017 Category: Drugs & Pharmacology Source Type: news

Laser May Be Safer Than Bevacizumab in Babies With Acute-phase ROP Laser May Be Safer Than Bevacizumab in Babies With Acute-phase ROP
Babies with acute-phase retinopathy of prematurity (ROP) who are treated with bevacizumab have more long-term eye problems than babies treated with laser, according to a new randomized controlled trial done in Italy.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 18, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Amgen and Allergan ’s anti-cancer biosimilar Mvasi receives FDA approval
The US Food and Drug Administration (FDA) has approved Mvasi (bevacizumab-awwb) for the treatment of five types of cancer. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 17, 2017 Category: Pharmaceuticals Source Type: news

FDA has approved biosimilar of Roche's Avastin
Amgen Inc. AMGN, -1.37% and Allergan AGN, -1.08% said Thursday that the Food and Drug Administration has approved their biosimilar version of Roche's Avastin for five types of cancer.09/15/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 15, 2017 Category: Urology & Nephrology Source Type: news

Mvasi Is First Biosimilar Drug Approved for Cancer
Similar to Avastin (Source: Cancercompass News: Other Cancer)
Source: Cancercompass News: Other Cancer - September 15, 2017 Category: Cancer & Oncology Source Type: news

FDA Approves First Biosimilar Drug for Cancer
Mvasi (bevacizumab - awwb) is biosimilar to Avastin (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 15, 2017 Category: Cancer & Oncology Tags: Gastroenterology, Gynecology, Internal Medicine, Nephrology, Oncology, Pharmacy, Pulmonology, Institutional, Source Type: news

Mvasi Is First Biosimilar Drug Approved for Cancer
Similar to Avastin (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 14, 2017 Category: Cancer & Oncology Tags: Oncology, Pharmacy, FDA Approvals, Source Type: news

FDA Approves Mvasi (bevacizumab-awwb), a Biosimilar to Avastin
September 14, 2017 -- The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 14, 2017 Category: Drugs & Pharmacology Source Type: news

FDA Approves Amgen And Allergan's MVASI ™ (bevacizumab-awwb) For The Treatment Of Five Types Of Cancer
Approval Based on Totality of Evidence From Global Development Program Showing MVASI™ is Highly Similar to Avastin® (bevacizumab) First Ever Biosimilar to Fight Cancer Approved by FDA THOUSAND OAKS, Calif., Sept. 14, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Allergan plc. (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved MVASI™ (bevacizumab-awwb) for all eligible indications of the reference product, Avastin® (bevacizumab). MVASI is the first anti-cancer biosimilar, as well as the first bevacizumab biosimilar, approved by the FDA. MVASI i...
Source: Amgen News Release - September 14, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

First Oncology Biosimilar Approved in US: Bevacizumab First Oncology Biosimilar Approved in US: Bevacizumab
The FDA has approved the first biosimilar for use in the treatment of cancer: Myasi, or bevacizumab-awwb (equivalent to Avastin).News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 14, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Mvasi Is First Biosimilar Drug Approved for Cancer
THURSDAY, Sept. 14, 2017 -- The first biosimilar drug to treat cancer has been approved by the U.S. Food and Drug Administration. Mvasi (bevacizumab-awwb) was found to be biosimilar to the anti-cancer drug Avastin, the FDA said Thursday in a news... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 14, 2017 Category: General Medicine Source Type: news

U.S. FDA approves biosimilar version of cancer drug Avastin
(Reuters) - The U.S. Food and Drug Administration said on Thursday it has approved Amgen Inc's biosimilar version of Roche Holding AG's cancer drug Avastin. (Source: Reuters: Health)
Source: Reuters: Health - September 14, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Avastin Clone OK'd
(MedPage Today) -- Biosimilar for bevacizumab approved for various cancers (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - September 14, 2017 Category: American Health Source Type: news

FDA approves first biosimilar for the treatment of cancer
The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the treatment of cancer. (Source: Food and Drug Administration)
Source: Food and Drug Administration - September 14, 2017 Category: American Health Source Type: news

FDA OKs First'Biosimilar' Drug to Fight Cancer, Mvasi
THURSDAY, Sept. 14, 2017 -- The first approval of a biosimilar drug to treat cancer was announced Thursday by the U.S. Food and Drug Administration. Mvasi (bevacizumab-awwb) was approved as a biosimilar to Avastin (bevacizumab) for the treatment of... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 14, 2017 Category: General Medicine Source Type: news

FDA approves first biosimilar for the treatment of cancer
The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the treatment of cancer. (Source: World Pharma News)
Source: World Pharma News - September 14, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

New technique gives a clearer image of immunotherapy results in advanced brain cancer
FINDINGSResearchers led by Robert Prins, a member of the UCLA Jonsson Comprehensive Cancer Center, have developed a new approach for brain imaging that can better distinguish immune responses from tumor growth in both preclinical studies and in people with glioblastoma.BACKGROUNDDespite clinical advances in immunotherapy for cancer, non-invasive monitoring of tumor growth (especially in people with brain tumors) has been a significant problem. When clinicians use traditional medical imaging processes, the inflammation that sometimes results from immunotherapies can resemble neurological decline and tumor growth.METHODPrins...
Source: UCLA Newsroom: Health Sciences - September 5, 2017 Category: Universities & Medical Training Source Type: news

Is Syringe Lubricant Causing Floaters After Eye Injection?
(MedPage Today) -- Complaints after bevacizumab injections may be due to syringe design (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - August 15, 2017 Category: General Medicine Source Type: news

Ophthotech eye-drug trial fails to meet primary endpoint
Shares in Ophthotech (NSDQ:OPHT) dipped to $2.46 apiece this morning after the company announced that its Phase III wet age-related macular degeneration trial failed to meet its primary endpoint. The New York-based company said that the addition of Fovista (pegpleranib) to Eylea or Avastin, both anti-VEGF therapies, did not significantly improve visual acuity after 12-months compared to Eylea or Avastin alone. Get the full story at our sister site, Drug Delivery Business News. The post Ophthotech eye-drug trial fails to meet primary endpoint appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - August 14, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Wall Street Beat ophthotech Source Type: news

Adding Bevacizumab to Chemo Boosts Survival in Advanced Cervical Cancer Adding Bevacizumab to Chemo Boosts Survival in Advanced Cervical Cancer
The overall survival (OS) benefit seen with bevacizumab in advanced cervical cancer persists with extended follow-up, new research shows.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 7, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Pfizer announces positive top-line results from the comparative REFLECTIONS B7391003 study for PF-06439535, a potential biosimilar to Avastin ® (bevacizumab)
Pfizer Inc. (NYSE:PFE) has announced that the REFLECTIONS B7391003 study, a comparative, confirmatory safety and efficacy study of PF-06439535 versus Avastin®(1) (bevacizumab), met its primary objective. PF-06439535 is being developed by Pfizer as a potential biosimilar to Avastin. (Source: World Pharma News)
Source: World Pharma News - July 25, 2017 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Biosimilars to Avastin and Herceptin Head for US Market Biosimilars to Avastin and Herceptin Head for US Market
Two new biosimilars, bevacizumab and trastuzumab, were unanimously recommended for approval by an FDA oncologic advisory committee.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 14, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Biosimilars Get Clean Sweep at FDA Hearings
(MedPage Today) -- Unanimous backing for Herceptin biosimilar; follows identical vote for Avastin copy (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - July 13, 2017 Category: American Health Source Type: news

ODAC Gives Thumbs Up to Avastin Biosimilar
(MedPage Today) -- Unanimous recommendation for FDA approval (Source: MedPage Today Urology)
Source: MedPage Today Urology - July 13, 2017 Category: Urology & Nephrology Source Type: news

Amgen And Allergan To Discuss Data Supporting Biologics License Application For ABP 215, A Biosimilar Candidate To Avastin ® (bevacizumab)
First Amgen and Allergan Oncology Biosimilar Candidate to be Reviewed by U.S. FDA Advisory Committee THOUSAND OAKS, Calif., July 13, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced that the Companies will discuss data supporting the ABP 215 Biologics License Application (BLA) with the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA). ABP 215 is a biosimilar candidate to Avastin® (bevacizumab) and is the first bevacizumab biosimilar candidate to be considered by the FDA. "Amgen has worked diligently to apply our more tha...
Source: Amgen News Release - July 13, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Intravitreal Bevacizumab Via Insulin Syringe Tied to Oil Droplets Intravitreal Bevacizumab Via Insulin Syringe Tied to Oil Droplets
Bevacizumab prepared in insulin syringes is associated with an increase in intravitreal silicone oil droplets in patients using the medication, as well as a higher risk of floaters, researchers in California say.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 26, 2017 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Bevacizumab Fails to Improve Survival in Resected High-Risk Melanoma
Treatment with single-agent bevacizumab resulted in an improved disease-free interval in patients with resected melanoma, but no increase in overall survival compared with observation. (Source: CancerNetwork)
Source: CancerNetwork - June 25, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Melanoma News Source Type: news

Similar Efficacy for Key Anti-VEGF Agents in Macular Edema Similar Efficacy for Key Anti-VEGF Agents in Macular Edema
The SCORE2 trial shows that bevacizumab and aflibercept may produce similar short-term outcomes. Here is a closer look at its results.Medscape Optometry (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 20, 2017 Category: Consumer Health News Tags: Ophthalmology Viewpoint Source Type: news

Aflibercept May Be Effective for Resistant Exudative AMD Aflibercept May Be Effective for Resistant Exudative AMD
Aflibercept appears to improve outcomes in patients with exudative age-related macular degeneration (AMD) resistant to treatment with ranibizumab or bevacizumab, researchers from Norway report.Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - June 14, 2017 Category: Opthalmology Tags: Ophthalmology News Source Type: news

MassDevice.com +5 | The top 5 medtech stories for June 8, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Sanuwave Health inks dev deal with eKare for wound care integration Sanuwave Health said today it entered a memorandum of understanding with eKare to develop novel wound care analysis and management solutions which integrates t...
Source: Mass Device - June 8, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Novocure launches Optune, chemotherapy combo trial for glioblastoma
Novocure (NSDQ:NVCR) said today that the 1st patient was enrolled in a Phase II pilot trial evaluating Optune with bevacizumab, a chemotherapy, for patients with refractory recurrent glioblastoma. In recurrent GBM, Optune and bevacizumab are approved as monotherapies. Novocure’s consortium study is slated to evaluate the efficacy and safety of the Optune-chemo combo in patients with bevacizumab-refractory recurrent GBM. Get the full story at our sister site, Drug Delivery Business News. The post Novocure launches Optune, chemotherapy combo trial for glioblastoma appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - June 8, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Neurological Oncology Pharmaceuticals Wall Street Beat NovoCure Source Type: news

Atezolizumab/Bevacizumab in Metastatic RCC Moves to Phase III Trial
This video reviews second-line data from the IMmotion150 trial, which initially studied atezolizumab with or without bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma patients. (Source: CancerNetwork)
Source: CancerNetwork - June 8, 2017 Category: Cancer & Oncology Authors: Michael B. Atkins, MD Tags: Conferences/ASCO Renal Cell Carcinoma News Videos Genitourinary Cancers Source Type: news

Amgen And Allergan Announce FDA Advisory Committee Meeting To Review ABP 215, A Biosimilar Candidate To Bevacizumab
THOUSAND OAKS, Calif., June 7, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE: AGN) today announced that the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review data supporting the Biologics License Application (BLA) for ABP 215, a biosimilar candidate to Avastin® (bevacizumab), on July 13, 2017. "Amgen has a long and proud heritage in oncology, and we are committed to providing physicians and patients a range of high quality therapeutic options," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "...
Source: Amgen News Release - June 7, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Bevacizumab Improves Responses, PFS in Advanced Head and Neck Cancer
This video highlights results of a phase III randomized trial that tested chemotherapy plus bevacizumab in patients with recurrent or metastatic head and neck cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 6, 2017 Category: Cancer & Oncology Authors: Barbara Burtness, MD Tags: Conferences/ASCO Street Team Head & Neck Cancer News Source Type: news

Bevacizumab Does Not Improve Response, Survival in Ovarian Cancer
Adding bevacizumab to neoadjuvant chemotherapy did not improve complete macroscopic response rate or progression-free survival in women with ovarian cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Conferences/ASCO Ovarian Cancer News Source Type: news

Minimal Differences Between Anti-VEGF Drugs on IOP Over Time Minimal Differences Between Anti-VEGF Drugs on IOP Over Time
Patients on anti-VEGF therapy may have a small decrease in intraocular pressure (IOP) over time, but with minimal differences between aflibercept, ranibizumab, and bevacizumab, a new large study suggests.Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - June 1, 2017 Category: Opthalmology Tags: Ophthalmology News Source Type: news